More on Biogen Inc. – Will They or Won’t They?

February 22, 2021 Kira Domratchev In the News Tags: , , , 0 Comments

I recently blogged about Biogen Inc. and the drug in development that is said to be the first treatment that could show decline in people with Alzheimer’s disease.

Since I wrote about this in November, 2020, Biogen has continued working towards the coveted regulatory approval from the U.S. Food and Drug Administration (FDA).

Despite a panel of experts at the FDA voting against the drug in November, 2020, the FDA has extended the review period of the drug by three months. For reference, the panel voted “no” to three questions related to whether a single successful large trial of the drug was sufficient evidence of the drug’s effectiveness, given the clear failure of a second large study.

Although the FDA is not obligated to follow the recommendations of the panel, it usually does.

Notwithstanding the FDA’s history of following the panel’s recommendations, this extension raised some hopes that the drug may still be approved which reflected in an increase of Biogen’s shares by 8% premarket.

Obtaining regulatory approval would certainly be of benefit to the shareholders of Biogen. However, if the drug is actually effective, it would certainly change the lives of many people afflicted with Alzheimer’s today.

Stay tuned for more updates!

Thanks for reading.

Kira Domratchev

Find this blog interesting? Please consider these other related posts:

Dementia in the News

Introduction of National Dementia Strategy

New Model of Care for Those with Dementia Coming to Canada

Leave a reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE TO OUR BLOG

Enter your email address to subscribe to this blog and receive notifications of new posts by email.
 

CONNECT WITH US

TRY HULL E-STATE PLANNER SOFTWARE

Hull e-State Planner is a comprehensive estate planning software designed to make the estate planning process simple, efficient and client friendly.

Try it here!

CATEGORIES

ARCHIVES

TWITTER WIDGET

  • To Consolidate or Not to Consolidate: James v. Estate of Clarence Roy James et al. Read about the three separate b… https://t.co/0dHaTzWdhB
  • The latest episode of our podcast is now live! Hull on Estates #627 – What is the Role of the Office of the Public… https://t.co/gIVTsdvjIC
  • Costs in SDA Proceedings: A Lesson from Rudin-Brown Today's article delves into the costs decision of Rudin-Brown… https://t.co/xoakfVgo4n
  • The Intersection of Family and Estate Issues – Does an estate have to pay retroactive child support? Last Monday's… https://t.co/Q1gCHnS6xY
  • Hundreds affected by IVF doctor’s alleged improper actions. Read today's article here: https://t.co/dDxepM30Ci… https://t.co/D0il5nbkuI
  • Today's article highlights some key take aways from the paper: “The Annotated Guardianship Application – The View F… https://t.co/WaEM4anqQv